Page last updated: 2024-12-11
cinodine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
cinodine: glycocinnamoylspermidine antibiotic; gyrase inhibitor found in Nocardia; RN given refers to cpd with unknown MF [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6436146 |
| MeSH ID | M0106103 |
Synonyms (11)
| Synonym |
|---|
| ll-bm 123 gamma |
| antibiotic bm 123gamma |
| cinodine |
| antibiotic ll-bm 123 gamma |
| bm 123 gamma |
| antibiotic bm 123 gamma |
| 52932-64-6 |
| vxo32pv6q1 , |
| unii-vxo32pv6q1 |
| (e)-3-[4-[(2r,3r,4s,5s,6r)-5-[[(2s,3r,4r,5r)-5-[[(3as,6s,7r,7ar)-7-(carbamoylamino)-2-oxo-1,3a,4,6,7,7a-hexahydropyrano[4,3-d][1,3]oxazol-6-yl]oxy]-3-(carbamoylamino)-4-hydroxyoxan-2-yl]carbamoylamino]-3-(diaminomethylideneamino)-4-hydroxy-6-methyloxan-2- |
| (e)-n-(3-((4-aminobutyl)amino)propyl)-3-(4-(((2r,3r,4s,5s,6r)-3-guanidino-4-hydroxy-5-(3-((2s,3r,4r,5r)-4-hydroxy-5-(((3as,6s,7r,7ar)-2-oxo-7-ureidohexahydro-2h-pyrano[4,3-d]oxazol-6-yl)oxy)-3-ureidotetrahydro-2h-pyran-2-yl)ureido)-6-methyltetrahydro-2h-p |
Research Excerpts
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cinodine was found to inhibit the activity of Micrococcus luteus DNA gyrase in vitro, but it did not inhibit the activities of two other DNA-binding enzymes, namely, topoisomerase I and BamHI." | ( In vitro inhibition of bacterial DNA gyrase by cinodine, a glycocinnamoylspermidine antibiotic. Greenstein, M; Maiese, WM; Osburne, MS, 1990) | 1.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||